Yihai Cao active positions
| Companies | Position | Start | End |
|---|---|---|---|
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Director/Board Member | 2005-12-31 | - |
| Founder | 2005-12-31 | - |
Career history of Yihai Cao
Former positions of Yihai Cao
| Companies | Position | Start | End |
|---|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - | - |
Training of Yihai Cao
| University of Copenhagen | Doctorate Degree |
Statistics
International
| Sweden | 3 |
| Denmark | 2 |
Operational
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Yihai Cao
- Experience
